Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers https://www.biorxiv.org/content/10.1101/2023.03.27.534309v1?med=mas
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers https://www.biorxiv.org/content/10.1101/2023.03.27.534309v1?med=mas